Pfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence…
Patent Rejection
23 articles
Intellectual Property (IP) in India: A Decade of Progress Part 10
The Traditional Knowledge Digital Library has played a pivotal role in India’s efforts to safeguard traditional knowledge from bio-piracy. This post outlines TKDL’s major milestones and its impartial…
‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C…